<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05010434</url>
  </required_header>
  <id_info>
    <org_study_id>SBRRHCC</org_study_id>
    <nct_id>NCT05010434</nct_id>
  </id_info>
  <brief_title>Sintilimab and Bevacizumab Combined With Radiotherapy for Advanced Recurrent Hepatocellular Carcinoma</brief_title>
  <official_title>Sintilimab and Bevacizumab Combined With Radiotherapy in the Treatment of Advanced Recurrent Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate both the efficacy and safety of sintilimab&#xD;
      combined with bevacizumab and radiotherapy in advanced recurrent hepatocellular carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR (objective response rate)</measure>
    <time_frame>1 year</time_frame>
    <description>the proportion of patients who have a partial or complete response to therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS (progression-free survival)</measure>
    <time_frame>1 year</time_frame>
    <description>defined as the time from receiving treatment until disease progression or death from any cause, whichever happens first. Patients who withdraw or who are lost to follow-up will be censored at the date last known to be alive and progression free. Patients not having an event will be censored at the date last seen alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR (disease control rate)</measure>
    <time_frame>1 year</time_frame>
    <description>the proportion of patients whose tumors have shrunk or been stable for a certain period of time, including cases of complete response (CR), partial response (PR), or stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS (overall survival)</measure>
    <time_frame>1 year</time_frame>
    <description>defined as the time from receiving treatment until death from any cause. Patients who withdraw or who are lost to follow-up will be censored at the date last known to be alive. Patients remaining alive throughout the duration of the study will have their survival time censored on the date last seen alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse effects</measure>
    <time_frame>1 year</time_frame>
    <description>adverse effects of sintilimab and bevacizumab combined with radiotherapy,number of participants with treatment-related adverse events as assessed by CTCAE v5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Recurrent Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sintilimab and Bevacizumab Combined with Radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab and Bevacizumab Combined with Radiotherapy</intervention_name>
    <description>Before radiotherapy: Bevacizumab+Sintilizumab, Q3w, 2 cycles in total. Radiation therapy: 30-50Gy/10 fractions. After radiotherapy: Bevacizumab+Sintilizumab, Q3w until disease progression or toxicity is intolerable.</description>
    <arm_group_label>Sintilimab and Bevacizumab Combined with Radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: 18-75 years;&#xD;
&#xD;
          2. ECOG (Eastern Cooperative Oncology Group) 0-1;&#xD;
&#xD;
          3. Locally advanced or advanced recurrent hepatocellular carcinoma (HCC) that cannot be&#xD;
             surgically removed;&#xD;
&#xD;
          4. Have not received anti-tumor system therapy;&#xD;
&#xD;
          5. At least 1 measurable lesion (according to RECIST 1.1);&#xD;
&#xD;
          6. Child-Pugh Class A;&#xD;
&#xD;
          7. At least 12 weeks of life expectancy;&#xD;
&#xD;
          8. Adequate hematologic, hepatic and renal function: Hb ≥ 90g/L, ANC(absolute neutrophil&#xD;
             count) ≥ 1.5x10^9/L, PLT(platelet count) ≥60 x10^9/L, ALT(alanine aminotransferase)&#xD;
             and AST(aspartate aminotransferase) ≤3×ULN(upper limit of normal), total bilirubin&#xD;
             ≤1.5×ULN, serum creatinine ≤1.5×ULN, albumin ≥ 30g/L;&#xD;
&#xD;
          9. Contraception during the study;&#xD;
&#xD;
         10. Willing to join the study and sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. HCV (hepatitis C virus) infection.&#xD;
&#xD;
          2. History of allergy to anti-PD-1 (PD-1, programmed cell death protein 1) monoclonal&#xD;
             antibody and anti-VEGF (VEGF, vascular endothelial growth factor) monoclonal antibody.&#xD;
&#xD;
          3. Have other malignant tumors within 5 years, except for fully treated skin basal cell&#xD;
             cancer and cervical cancer;&#xD;
&#xD;
          4. Poor blood pressure control. In the case of taking medication, systolic blood&#xD;
             pressure&gt;140mmHg or diastolic blood pressure&gt;90mmHg.&#xD;
&#xD;
          5. Received radiotherapy for liver disease.&#xD;
&#xD;
          6. History of hepatic encephalopathy.&#xD;
&#xD;
          7. Received transplantation.&#xD;
&#xD;
          8. Severe pleural effusion, ascites or pericardial effusion.&#xD;
&#xD;
          9. History of autoimmune diseases and autoimmune deficiency.&#xD;
&#xD;
         10. Receiving systemic glucocorticoid therapy or any other form of immunosuppressive&#xD;
             therapy within 7 days before the first administration.&#xD;
&#xD;
         11. Active infections that require systemic treatment, such as active tuberculosis.&#xD;
&#xD;
         12. History of idiopathic pulmonary fibrosis, tissue pneumonia, drug-induced pneumonia or&#xD;
             idiopathic pneumonia, or active pneumonia found in chest CT examination.&#xD;
&#xD;
         13. Severe bleeding.&#xD;
&#xD;
         14. Esophageal and gastric varices with high risk of bleeding and not fully treated;&#xD;
             rupture of esophageal and gastric varices occurred within 6 months before the first&#xD;
             administration.&#xD;
&#xD;
         15. Required daily treatment with non-steroidal anti-inflammatory drugs (NSAID).&#xD;
&#xD;
         16. Accompanying diseases that seriously endanger the safety of the patient or affect the&#xD;
             completion of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shuang Wu, doctor</last_name>
    <phone>+862087755766</phone>
    <email>wush77@mail.sysu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuang Wu</last_name>
      <phone>+862087755766</phone>
      <email>wush77@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 14, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Affiliated Hospital, Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Zhen-Wei Peng</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

